MBD2 and ovarian serous adenocarcinoma: [45], it was found that 63.5% of 73 tissue samples from high‐grade serous ovarian cancer (HGSOC) exhibited positive expression of MBD2, while the expression level of MBD2 was undetectable in all 16 normal tissue samples (100%).